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Hyperglycaemia up‑regulates 
placental growth factor (PlGF) 
expression and secretion 
in endothelial cells via suppression 
of PI3 kinase‑Akt signalling 
and activation of FOXO1
Samir Sissaoui1,5, Stuart Egginton2, Ling Ting1, Asif Ahmed3,4 & Peter W. Hewett1*
Placenta growth factor (PlGF) is a pro‑inflammatory angiogenic mediator that promotes many 
pathologies including diabetic complications and atherosclerosis. Widespread endothelial dysfunction 
precedes the onset of these conditions. As very little is known of the mechanism(s) controlling 
PlGF expression in pathology we investigated the role of hyperglycaemia in the regulation of PlGF 
production in endothelial cells. Hyperglycaemia stimulated PlGF secretion in cultured primary 
endothelial cells, which was suppressed by IGF‑1‑mediated PI3K/Akt activation. Inhibition of PI3K 
activity resulted in significant PlGF mRNA up‑regulation and protein secretion. Similarly, loss or 
inhibition of Akt activity significantly increased basal PlGF expression and prevented any further 
PlGF secretion in hyperglycaemia. Conversely, constitutive Akt activation blocked PlGF secretion 
irrespective of upstream PI3K activity demonstrating that Akt is a central regulator of PlGF expression. 
Knock‑down of the Forkhead box O‑1 (FOXO1) transcription factor, which is negatively regulated 
by Akt, suppressed both basal and hyperglycaemia‑induced PlGF secretion, whilst FOXO1 gain‑
of‑function up‑regulated PlGF in vitro and in vivo. FOXO1 association to a FOXO binding sequence 
identified in the PlGF promoter also increased in hyperglycaemia. This study identifies the PI3K/Akt/
FOXO1 signalling axis as a key regulator of PlGF expression and unifying pathway by which PlGF may 
contribute to common disorders characterised by endothelial dysfunction, providing a target for 
therapy.
Diabetes mellitus is associated with both central and peripheral vasculopathies, notably diabetic  retinopathy1. 
Patients also have an increased incidence of cardiovascular disease (CVD), susceptibility to associated complica-
tions such as plaque rupture and atherothrombosis, and approximately 75% die from vascular-related  disease1,2. 
Intensive management of blood glucose significantly reduces the risk of microvascular  complications3. Excessive 
superoxide anion generation in the mitochondria was proposed as the common mechanism underlying vascular 
injury in response to hyperglycaemia, although other factors such as insulin resistance, diabetic dyslipidemia, and 
advanced glycation end products contribute in type-2  diabetes2,4,5. Alterations in endothelial function precede 
the onset of diabetic complications, and are characterised by reduced endothelial nitric oxide (NO) synthase 
activity, elevated levels of inflammatory and coagulation markers, and increased endothelial cell  apoptosis6.
The phosphoinositide-3’-kinase (PI3K)/Akt (PKB) pathway is important for both mature endothelial cell and 
progenitor cell  function7,8 and its activity is reduced in both type-1 and type-2 diabetes  mellitus6. Several mecha-
nisms may contribute to the down-regulation of PI3K signalling in type-2 diabetes including the up-regulation 
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of TBR3, a CDC25 binding protein homolog, which directly inhibits Akt  activity9, and induction of the PI3K 
antagonist PTEN (phosphatase and tensin and homologue deleted on chromosome 10)10. Alternatively, there 
may be reduced levels of ligands and/or receptor activity coupled to this pathway.
Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family that 
mediate vascular development and homeostasis. Like VEGF, PlGF is a pleiotropic cytokine that promotes angio-
genesis, vascular remodelling, cell survival and  inflammation11. PlGF acts via the VEGF receptor-1 (VEGFR-1) 
and neuropilin accessory receptors, but leads to the phosphorylation of different VEGFR-1 tyrosine residues 
and gene expression to those activated by VEGF-A12. The expression of PlGF is low, or absent, in most healthy 
adult tissues and its activity is reported to be confined to pathological situations such as diabetes, atherosclerosis, 
arthritis and cancer making it an attractive target for  therapy11.
Our laboratory reported high vitreous PlGF levels in patients with proliferative diabetic  retinopathy13, which 
was confirmed by  others14,15. The intravitreous or systemic delivery of PlGF in rodents disrupts retinal barrier 
function and increases vascular leakage in a VEGFR-1-dependent manner, mimicking diabetic  retinopathy15,16. In 
addition, administration of soluble VEGFR-1 receptor (sFlt-1), which sequesters both PlGF and VEGF, prevents 
diabetic retinopathy in a spontaneous rat  model11,17. Furthermore, delivery of an anti-PlGF antibody in a mouse 
diabetic retinopathy model reduced vascular leakage, inflammation and  fibrosis18. Elevated circulating PlGF levels 
are associated with vascular inflammation and adverse outcome in patients with acute coronary  syndrome19, 
severity of metabolic  syndrome20, development of type-2  diabetes21 and childhood  obesity22. Increased PlGF 
expression in atherosclerotic plaques correlate with plaque instability, inflammation and intimal  angiogenesis23. 
In atherosclerosis-prone apolipoprotein E deficient  (ApoE−/−) mice, PlGF is up-regulated in early lesions and loss 
of PlGF reduces plaque size and macrophage  content24,25. Interestingly, PlGF null mice also have a lower fat con-
tent when maintained on a high-fat  diet26. However, the mechanism(s) by which PlGF expression is up-regulated 
in these pathologies remain unknown. In this study we show that manipulation of glucose concentration, PI3K 
or Akt activity leads to consistent changes in endothelial cell PlGF expression and release, which are dependent 
on FOXO1 transcription factor activity. The identification of the involvement of the PI3K/Akt/FOXO1 pathway 
in the control of PlGF expression may have important implications for endothelial homeostasis and dysfunction, 
and therefore represent a target for therapy in vascular disorders.
Results
PlGF expression is modulated by hyperglycaemia in endothelial cells. Elevated circulating PlGF 
has recently been identified in insulin resistance, metabolic syndrome, vascular inflammation and is an inde-
pendent marker of the future development of type-II  diabetes19–22. To determine whether hyperglycaemia up-
regulates the expression of PlGF, we incubated confluent primary human endothelial cells in medium containing 
30 mM d-glucose for 24 h and measured the level of PlGF released into the medium by ELISA. Hyperglycaemia 
significantly up-regulated PlGF release from HUVEC (Fig. 1A) and HAEC (Fig. S1) compared with cells main-
tained under normal glucose levels (5 mM d-glucose) or osmolarity controls (25 mM l-glucose + 5 mM d-glu-
cose). As hyperglycaemia is reported to suppress PI3K signalling in many cell types, including endothelial  cells26 
we examined the effect of the established PI3K activators, IGF-1 and insulin on PlGF expression. The basal level 
of PlGF produced by endothelial cells was reduced in a concentration-dependent manner by IGF-1 (Fig. 1B) 
and insulin (1 mM) led to a 31% decrease in PlGF secretion (data not shown), indicating that PlGF release is 
negatively regulated by PI3K pathway activity in endothelium. Furthermore, addition of IGF-1 (10 ng/ml) sig-
nificantly reduced the level of PlGF release in endothelial cells grown under both hyperglycaemic and normo-
glycaemic conditions (Fig. 1C and Fig. S1). The inhibitory effect of hyperglycaemia on PI3K activity in HUVEC 
and its modulation with IGF-1 (10 ng/ml) were demonstrated by Western blotting for phoshorylation of Akt 
at Serine 473  (pAktSer473). The level of activity  (pAktSer473) was found to be decreased by hyperglycaemia under 
both basal conditions and following IGF-1 stimulation in comparison with cells in normoglycaemia (Fig. 1D).
Up-regulation of PlGF expression was reported to be dependent on endogenous VEGF in bovine retinal 
endothelial  cells27. To determine whether endogenous VEGF was involved in the observed up-regulation of 
PlGF in hyperglycaemia, VEGF was knocked-down in HUVEC prior to exposure to 30 mM d-glucose (Fig. S2). 
Surprisingly, knock-down of endogenous VEGF expression was found to promote PlGF mRNA expression and 
secretion under control conditions (Fig. S2A-C) and in the presence of hyperglycaemia indicating that PlGF 
production in hyperglycaemia is not secondary to the induction of endogenous VEGF (Fig. S2D). This also 
consistent with an observed decrease in Akt phosphorylation 24 h after the knock-down of endogenous VEGF 
(data not shown).
PI3K signalling negatively regulates PlGF expression in endothelial cells. To establish the 
involvement of the PI3K pathway in controlling PlGF expression, HUVEC were incubated with the PI3K inhibi-
tor, LY294002, and PlGF expression and release examined by real-time qPCR and ELISA. Blockade of PI3K 
resulted in a significant increase in both PlGF mRNA and protein release (Fig. 2A,B). In addition, the use of 
recombinant adenoviruses encoding the PI3K antagonist, PTEN, produced a similar increase in PlGF release 
from HUVEC, whilst cells infected with a catalytically inactive PTEN mutant (PTENc/s) were not affected 
(Fig. 2C). Western blotting was performed to confirm that LY294002 treatment and PTEN over-expression led 
to a decrease in the activation of the downstream PI3K effector, Akt (Fig.  2D,F). This was demonstrated by 
the greatly reduced levels of phosphorylation of Akt serine 473  (pAktSer473). Furthermore, no further increase 
in PlGF release was observed from HUVEC cultured in medium containing 30 mM d-glucose following pre-
treatment with LY294002, indicating that hyperglycaemia stimulates PlGF expression via its inhibitory action 
on the PI3K pathway (Fig. 2E).
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Akt is a negative regulator of PlGF expression in endothelial cells. To determine whether PI3K 
acts via Akt to regulate PlGF expression, endothelial cells were infected with adenoviruses encoding either dom-
inant-negative (dn-Akt), or constitutively active myristolated (myr-Akt) mutants of Akt. Following infection of 
HUVEC with dn-Akt adenoviruses (see Fig. S3), the levels of PlGF mRNA and protein released into the culture 
medium increased significantly compared with cells treated with control virus encoding β-galactosidase (β-gal) 
(Fig.  3A,B). To further establish the central role of Akt in the regulation of PlGF expression, HUVEC were 
infected with different combinations of either PTEN or β-gal with PTEN, myr-Akt or β-gal adenoviruses to 
maintain equal viral load. Over-activation of Akt dramatically reduced the increase in PlGF release stimulated 
by PTEN-mediated blockade of the PI3K pathway, demonstrating that Akt is the key downstream effector regu-
lating PlGF expression (Fig. 3C). Moreover, the involvement of Akt activity in the hyperglycaemic induction of 
PlGF was confirmed by the over-expression of myr-Akt, which inhibited hyperglycaemia-induced PlGF release 
(Fig. 3D).
Akt-1 is the predominant isozyme of Akt in the vasculature and is involved with the regulation of sev-
eral IGF-1 target genes and implicated in various  pathologies6. The siRNA–mediated knock-down of Akt-1 in 
HUVEC (Fig. 3E) significantly increased PlGF secretion into the culture medium (Fig. 3F). In contrast to nor-
moglycaemia and the osmolarity control, the loss of Akt1 did not result in any further increase of PlGF secretion 
compared with control siRNA treated cells under hyperglycaemic conditions (Fig. 3G). Collectively, our findings 
show that Akt is a negative regulator of PlGF production in endothelial cells.
Figure 1.  Hyperglycaemia suppresses Akt activity and promotes PlGF secretion in endothelial cells. (a) 
Confluent endothelial cells cultured for 24 h in either normolycaemia (NG = 5 mM d-glucose), hyperglycaemia 
(HG = 30 mM d-glucose) or osmolarity control (OS = 5 mM d-glucose + 25 mM l-glucose) medium, and the 
level of PlGF secretion measured by ELISA. (b) Confluent HUVEC stimulated with increasing concentrations 
of IGF-1 in medium containing 10% FCS for 24 h and PlGF secretion measured by ELISA. (c) HUVEC were 
cultured in medium containing either NG, HG or OS control in the presence of IGF-1 (10 ng/ml) for 24 h 
and PlGF secretion quantified by ELISA. (d) Confluent HUVEC were maintained in NG, HG or OS control 
conditions and then stimulated with IGF-1 (10 ng/ml) or vehicle for 10 min and cell lysates Western blotted for 
phospho-AktSer473  (pAktSer473), total Akt and β-actin. The unedited blot images are presented in Supplementary 
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Figure 2.  Inhibition of the PI3K pathway promotes PlGF expression and secretion. Confluent HUVEC 
pre-treated with LY294002 (20 µM) and incubated for (a) 8 h or (b) 24 h and PlGF mRNA quantified by 
qPCR and protein secretion by ELISA. (c) HUVEC were infected overnight with adenoviruses encoding 
PTEN, mutant PTEN (PTEN-c/s), or β-galactosidase (β-gal). Following 24-h incubation (c) PlGF levels in the 
culture medium were quantified by ELISA. (d) Western blots confirming inhibition of Akt activity in HUVEC 
following Ad-PTEN infection. (e) HUVEC treated with LY294002 or the vehicle and incubated for 24 h in 
normoglycaemia (NG = 5 mM d-glucose), hyperglycaemia (HG = 30 mM d-glucose), or osmolarity control 
(OS = 5 mM d-glucose + 25 mM l-glucose), and PlGF measured in supernatants by ELISA. (f) Representative 
Western blots of the HUVEC lysates following treatment of HUVEC with LY294002 or the vehicle for one 
hour showing  pAktSer473, total Akt with β-actin as a loading control. The unedited blot images are presented in 
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Figure 3.  Inhibition of Akt activity increases PlGF production. HUVEC were transduced with adenoviruses 
encoding dominant-negative Akt (dn-Akt), constitutively active Akt (myr-Akt) and β-galactosidase (β-gal). 
Following (a) 8 h and (b) 24-h incubation PlGF expression and secretion was quantified by qPCR and 
ELISA. (c) HUVEC were co-infected with combinations of PTEN, myr-Akt and β-gal (control) adenoviruses 
overnight. After 24 h PlGF secretion was quantified by ELISA. (d) HUVEC were transduced with myr-Akt or 
β-gal and incubated in normoglycaemia (NG = 5 mM d-glucose), hyperglycaemia (HG = 30 mM d-glucose) 
or osmolarity control (OS = 5 mM d-glucose + 25 mM l-glucose), and PlGF release into the culture medium 
measured by ELISA. (e - g) HUVEC were electroporated with siRNA targeted to Akt-1 (siAkt) or control siRNA 
(siControl). (e) PlGF measured after 24 h in cell supernatants and (f) the cell lysates Western blotted for Akt and 
β-actin (unedited blot images in Supplementary Figure S5). (g) Cells were incubated in NG, HG or OS for 24 h 
and PlGF release measured by ELISA. Results are the mean ± SEM of 3 or more experiments (n = ≥ 6); Student’s 
t-test, *P < 0.05, **P < 0.01.
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FOXO1 promotes PlGF expression in endothelial cells following hyperglycaemia. The forkhead 
box O (FOXO) transcription factors are inversely regulated by Akt activation through phosphorylation, which 
leads to inhibition of DNA binding and their exclusion from the  nucleus28. FOXO1 is the predominant FOXO 
expressed in the vasculature, adipose tissue, liver and pancreas and is closely linked to glucose metabolism and 
the regulation of insulin/IGF-1-sensitive  genes28. Consistent with our findings of reduced Akt activity (Fig. 1D), 
the level of FOXO1 Serine 256 phosphorylation  (pFOXO1Ser256) decreased in these cells following exposure to 
hyperglycaemia indicating an increase of FOXO1 activity (Fig. 4A). Treatment of HUVEC with IGF-1 led to 
large increase FOXO1 phosphorylation/inhibition in normoglycaemia and the osmolarity control. There was a 
marked reduction in the level of  pFOXO1Ser256 in cells incubated with IGF-1 in hyperglycaemia (30 mM glucose) 
(Fig. 4A). These findings are consistent with the reduced level of Akt phosphorylation under these conditions 
(Fig. 1D). Similar effects on FOXO1 phosphorylation were also observed following infection of HUVEC with 
adenovirus expressing myr-Akt (Fig. S3). FOXO1 knock-down in HUVEC resulted in a significant decrease in 
PlGF mRNA expression and protein release demonstrating the importance of FOXO1 activity in basal PlGF 
release (Fig. 4B and Fig. S4). In contrast, knock-down of the closely related FOXO3A transcription factor did 
not affect PlGF expression or release (see Fig. S4). To confirm the requirement of FOXO1 in the hyperglycaemic 
induction of PlGF, HUVEC were incubated in medium containing 30 mM glucose following siRNA-mediated 
FOXO1 knock-down, which abrogated hyperglycaemia-induced PlGF up-regulation (Fig. 4C). Consistent with 
these findings, the adenoviral-mediated over-expression of constitutively active FOXO1 (caFoxO1) induced a 
fourfold increase in PlGF production compared with the β-gal control (Fig. 4D). No reduction in PlGF levels 
were observed following IGF-1 stimulation of caFOXO1 transduced HUVEC in contrast to the significantly 
reduced PlGF release in the β-gal controls (Fig. 4D).
In silico analysis of the human PlGF gene sequence identified a FOXO concensus DNA binding sequence 
(containing the core 5’-AAA CAA -3’ motif) between − 3414 bp and − 3423 bp upstream of the PlGF transcrip-
tional start site. Enrichment of FOXO1 binding to this site was investigated using ChIP assays performed with 
qPCR amplification a 118 bp region flanking the putative FOXO1 binding site relative to a negative control 
DNA region (NegC). As an additional control, FOXO1 enrichment was also examined at a region flanking the 
TATAA box proximal to the PlGF transcriptional start site, and compared with the degree of DNA polymerase 
II (Pol II) enrichment at both sites. Endogenous FOXO1 binding was found to be enriched at the FOXO1 site 
in the PlGF promoter, which increased significantly (~ fourfold) in HUVEC cultured under hyperglycaemic 
conditions (Fig. 4E). As expected there was no endrichment of Pol II binding at this site irrespective of glycae-
mic conditions (Fig. 4E). Conversely, as expected significant enrichment of Pol II was detected proximal to the 
PlGF transcriptional start site under normoglycaemic conditions which increased (sixfold) in hyperglycaemia, 
consistent with the up-regulation of PlGF expression in hyperglycaemia (Fig. 4F). As expected there was no 
enrichment of FOXO1 at the transcriptional start site (Fig. 4F), or Pol II at the FOXO1 binding site (Fig. 4E) 
further demonstrating specificity of the chromatin precipitation. Collectively, these data demonstrate that FOXO1 
activity is required for the direct induction of PlGF expression in hyperglycaemia.
FOXO1 promotes PlGF expression in vivo. To determine whether increased FOXO1 activity can regu-
late PlGF expression in  vivo, recombinant adenoviruses encoding either caFoxO1 (Ad-caFoxO1) or control 
empty virus (Ad-CMV) were delivered systemically to FVB/N mice. After 48 h the mice were culled and the 
levels of FoxO1 and Plgf mRNA in the liver and PlGF protein in plasma, quantified by qPCR and ELISA respec-
tively (Fig. 5). The level of FoxO1 mRNA was found to be increased the livers of the Ad-caFOXO1 group com-
pared with the Ad-CMV control group confirming adenoviral transduction (Fig. 5A). Figure 5B, shows that 
PlGF mRNA expression was significantly greater in the livers of mice receiving the Ad-caFoxO1 compared with 
Ad-CMV controls. Furthermore, circulating levels of PlGF in mice treated with caFoxO1 also increased signifi-
cantly compared with the Ad-CMV control group (Fig. 5C).
Discussion
The PI3K/Akt pathway is an important regulator of vascular homeostasis and loss of Akt activity results in 
endothelial dysfunction, which is a characteristic of diabetes, atherosclerosis, and the metabolic syndrome. In 
this study, we demonstrate that hyperglycaemia directly up-regulates PlGF by suppression of PI3K/Akt signalling 
resulting in an increase in FOXO1 activity and binding to the PlGF promoter in endothelial cells, and increased 
FOXO1 activity promotes PlGF expression in vivo. Akt phosphorylation is reported to be reduced by 50% in the 
internal mammary arteries of type-2 diabetic  patients27. Similarly, a loss of Akt activity is also reported in models 
of  diabetes26,29 and suppression of the PI3K antagonist PTEN restores Akt activity improving insulin sensitivity 
in mouse models of  diabetes10. Hyperglycaemia was reported previously to inhibit the PI3K/Akt pathway in vitro 
in rat retinal endothelial  cells26. This is consistent with our findings of reduced Akt phosphorylation in HUVEC 
incubated under hyperglycaemia, both under basal conditions and in the presence of IGF-1, and correspond-
ing changes in FOXO1 phosphorylation/activity in these cells. This resulted in increased FOXO1 binding to 
the PlGF promoter in HUVEC incubated under hyperglycaemic conditions. These findings are supported by 
a concomitant increase in Pol II enrichment in the region proximal to the PlGF transcriptional start site. Our 
data also show that Akt is the major downstream PI3K effector involved in PlGF production. The role of PI3K 
in PlGF expression was demonstrated by direct manipulation of the PI3K/Akt pathway using pharmacological 
inhibitors, recombinant IGF-1, or over-expression of wild-type and mutant signalling proteins in endothelial 
cells. Over-expression of myr-Akt, in the presence of PTEN-mediated inhibition of PI3K, or hyperglycaemia, 
markedly attenuated PlGF release. Knock-down of Akt1 in endothelial cells produced a similar increase in PlGF 
production to the general inhibition of Akt activity following over-expression of a dominant-negative Akt mutant, 
highlighting the importance of the Akt1 isozyme in regulating PlGF production. Akt1 is the predominant form 
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Figure 4.  Increased FOXO1 activity induces PlGF expression and release. (a) Confluent HUVEC were 
maintained in normoglycaemia (NG = 5 mM l-glucose), hyperglycaemia (HG = 10, or 30 mM d-glucose) or 
osmolarity control medium (OS = 5 mM d-glucose + 25 mM l-glucose) and then stimulated with IGF-1 (10 ng/
ml) for 10 min, and cell lysates Western blotted for phospho-FOXO1ser256, FOXO1 and β-actin (reused from 
Fig. 1d), with unedited blot images in Supplementary Fig. S5. (b) HUVEC were electroporated with FOXO1 
(siFOXO1) or control (siControl) siRNAs PlGF secretion into the culture medium quantified by ELISA. (c) 
HUVEC were cultured in NG, HG, or OS for 24 h and stimulated with IGF-1 (10 ng/ml) for 10 min. (d) 
HUVEC infected with ca-FoxO1 and Ad-CMV (control) adenoviruses overnight, then incubated with IGF-1 
(10 ng/ml) and PlGF quantified in cell supernatants by ELISA. Quantitative PCR detection of FOXO1 and Pol II 
enrichment to (e) the identified FOXO1 DNA binding site in the PlGF promoter and (f) region containing the 
TATAA box proximal to the PlGF transcription start site, relative to negative control DNA region (NegC) using 
ChIP assays. Results are the mean (± SEM) of ≥ 3 independent experiments and analysed using (b–d) Student’s 
t-test and (e,f) one-way ANOVA, Tukey’s post hoc test; *P < 0.05, **P < 0.01.
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of Akt in the  vasculature30 and its loss leads to severe atherosclerosis in  ApoE−/−  mice6. It is interesting to note 
that PCR array data from the same study, indicate that PlGF is up-regulated in mice fed a high fat diet following 
deletion of Akt1 on an  ApoE−/−  background6.
In contrast to our findings, a study using bovine retinal endothelial cells found that hyperglycaemia induced 
PlGF expression indirectly via an autocrine VEGF-dependent mechanism, based on the use of a VEGF receptor-2 
 inhibitor27. In our hands, VEGF knock-down in HUVEC did not reduce PlGF expression, as would be expected 
if PlGF production was secondary to the induction of endogenous VEGF. On the contrary, loss of endogenous 
VEGF expression was found to promote PlGF expression and secretion significantly (Fig. S2). Furthermore, the 
observed time-frame of PlGF mRNA induction in response to hyperglycaemia in this study was not consistent 
with PlGF release dependent on the up-regulation of VEGF expression. However, our findings are in line with 
more recent studies which show that endogenous VEGF suppresses FOXO1 activity in endothelial cells in an 
autocrine  manner31,32. Finally, PlGF up-regulation following stimulation of endothelial cells with recombinant 
VEGF was reported to be via PKC signalling and independent of PlGF gene  transcription33.
We have previously examined the level of PlGF production in many human primary and transformed cell 
types, and apart from trophoblast-derived cell lines (HTR-8/pSVneo, JAR) and thyroid cells the most significant 
source appears to be both microvascular and large vessel endothelial cells. Indeed, PlGF was reported to be the 
most abundant VEGF family member expressed in human dermal microvascular endothelium, detected at 100-
fold greater levels than the least abundant, VEGF-A34. In murine fibroblasts and a human choriocarcinoma cell 
line, PlGF was reported to be induced by hypoxia through the metal-responsive transcription factor, MTF-135,36. 
PlGF is switched on selectively in the embryonic kidney by the epithelium-specific BF-2 (FOXD2) transcription 
 factor37, and the forkhead-related transcription factor, glial cell missing-1 (GCM-1), regulates PlGF expression 
in trophoblast cell  lines38,39. In addition, heme-bound iron has been shown to up-regulate PlGF in erythroid cells 
via the erythroid krüppel-like factor (EKLF/KLF-1)40. However, there is a paucity of information on the control 
of PlGF expression in endothelial cells. Using siRNA-mediated knock-down or over-expression of constitutively 
active FOXO1, we demonstrate that PlGF expression is regulated directly by FOXO1 activity in endothelial 
cells. Furthermore, the increase in PlGF release in response to hyperglycaemia was lost in HUVEC following 
knock-down of FOXO1, and no IGF-1-mediated suppression of PlGF production was observed in the presence 
of constitutively active FOXO1. Moreover, FOXO-1 binding was detected at a FOXO-1 consensus DNA binding 
sequence identified in the PlGF promoter, and enriched ~ fourfold following exposure of the cells to hyperglycae-
mia. In contrast to our findings, the acute release of PlGF, assessed using protein arrays, from HAEC within one 
hour was reported to be associated with a loss of FOXO1 activity through C5b-9 complement complex activation 
of  Akt41. Conversely, in the same study FOXO1 knock-down actually prevented acute PlGF protein secretion, 
suggesting a differential regulatory role of FOXO1 in the transcription and secretion/release of  PlGF41. FOXO1 
is the predominant FOXO family member expressed in the vasculature, liver and pancreas and is associated 
Figure 5.  FOXO1 promotes PlGF expression in vivo. FVB/N mice were injected via the tail vein with 2 ×  1010 
infective units of Ad-caFoxO1, or Ad-CMV control virus (8 mice per group). After 48 h the mice were 
euthanised and blood and liver tissue collected. (a) PlGF and FoxO1 mRNA expression quantified in the liver 
by qPCR and (b) circulating PlGF was measured in plasma by ELISA. Results are the mean ± SEM of 8 mice per 
group; Student’s t test, *P < 0.05.
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with glucose metabolism and the regulation of insulin sensitive  genes5,42,43. FOXO1 haploinsufficiency in mice 
protects against obesity-related insulin  resistance44 and diet-induced  diabetes45, and in rat models of diabetes, 
FOXO1 knock-down in the vitreous reduces retinal endothelial apoptosis in  hyperglycaemia26. Furthermore, up-
regulation of FOXO1 activity in endothelial cells exposed to hyperglycaemia has been identified as a key response 
promoting oxidative stress through the up-regulation of inducible NO  synthase46. In addition to decreasing the 
level of FOXO1 phosphorylation this study showed that hyperglycaemia also reduces the level of FOXO1 acety-
lation which is associated increased transcriptional  activity46. The significance of endothelial FOXO1 activity in 
the promotion of atherosclerosis associated with insulin resistance has also been  highlighted5,47.
FOXO transcription factors are important modulators of vessel formation, maturation, maintenance and 
 homeostasis5,42,43,47–49. Indeed, FOXO1-deficient mice die in utero from embryonic day 9.5, exhibiting vascu-
lar defects in the aortic and branchial arches and failure to form blood vessels in the yolk  sac48,49. FOXO1 
was reported to be essential for in vitro vascular formation from embryonic stem  cells50, and over-expression 
or knock-down of either FOXO1 or FOXO3A in HUVEC leads to increased endothelial cell migration and 
capillary-like tube formation on growth factor-reduced  Matrigel50. Recently the importance of FOXO1 in regu-
lating endothelial cell quiescence has also been  highlighted43,49. Several genes involved in angiogenesis, vascular 
remodelling and maintenance/homeostasis, including angiopoietin-2 (Ang-2) are regulated by FOXO1, but not 
FOXO3A which is associated with  apoptosis42,51. Similarly, we find that FOXO3A does not regulate PlGF mRNA 
expression or protein release. Interestingly, microarray data from these studies and others indicate that FOXO1 
also regulates VEGFR-1 expression in endothelial  cells42,51,52. In pathologies, both PlGF and VEGFR-1 are fre-
quently up-regulated in the  endothelium11, and therefore the increased FOXO1 activity which is often observed 
in these conditions may provide a common mechanism by which both receptor and ligand are up-regulated to 
promote PlGF – VEGFR-1 signalling.
Insulin resistance, hyperglycaemia and diabetes are frequently associated with obesity, and are characteristics 
of the metabolic syndrome. In a cross-sectional survey conducted in three isolated populations in Southern 
Italy of 1000 men and women, circulating PlGF levels were significantly higher in subjects with the metabolic 
syndrome and correlated with the number of metabolic criteria in these  patients20. In addition, circulating PlGF 
is associated with obesity in children and correlated with troponin  levels22. PlGF mRNA is expressed in white 
adipose  tissue53, and  PlGF(−/−) knock-out mice have a lower body weight and fat content than wild-type mice 
and a lower fat content when maintained on a high-fat  diet54. Whether this is due to endothelial or adipocyte 
PlGF production was not fully established, but it suggests that in addition to increased risk of type II  diabetes21 
and  CVD19,23–25, up-regulation of PlGF in insulin resistance/hyperglycaemia and the metabolic syndrome may 
also accelerate the development of obesity.
PlGF is a key inflammatory mediator that activates monocytes, promoting migration and inflammatory 
cytokine and tissue factor  expression11,55,56. It is suggested that a major component of PlGF activity in pathologies 
may be through the induction of inflammatory infiltrates, rather than direct activation of the  endothelium11. 
However, both PlGF and VEGFR-1 are frequently up-regulated in the endothelium in  pathology11, and whilst 
it is established that the majority of endothelial VEGF responses are mediated via VEGFR-2, evidence from 
our laboratory and others has demonstrated that VEGFR-1 can act as a direct signalling receptor in endothelial 
 cells57–59, and PlGF-mediated VEGFR-1 activation leads to distinct endothelial gene expression to that of  VEGF12. 
The discovery that the PI3K/Akt/FOXO1 signalling axis regulates PlGF expression in endothelium is likely to 
be important for its pathological activity in diabetic retinopathy, atherosclerosis, and have wider implications 
in obesity and the metabolic syndrome, which are all characterised by endothelial dysfunction. Thus, it may 
represent a unifying pathway by which PlGF signalling may be up-regulated in these conditions and provide the 
basis for new approaches to limit its activity.
Methods
Cell culture. Human umbilical vein endothelial cells (HUVEC) were either isolated, characterised and cul-
tured essentially as described  previously57 from umbilical cords  obtained following informed consent under 
ethical approval [15-014-014] of the Human Biomaterials Resource Centre, University of Birmingham, UK. 
Pooled HUVEC from multiple donors were also purchased from PromoCell and human aortic endothelial cells 
(HAEC) from Lonza and maintained in their endothelial cell growth media and according to the supplier’s 
recommendations. Endothelial cells were routinely plated on 0.1% gelatin-coated tissue culture flasks/plates 
and experiments were performed using cells at the third or fourth passage. For experiments to examine PlGF 
secretion endothelial cells (1 ×  105 cells/well) were plated in 24-well plates with 0.5 ml of growth medium to 
produced confluent monolayers and incubated for 24 h. The medium was then replaced with 0.5 ml MCDB131 
(Invitrogen) containing 10% FCS and cells incubated for a further 24 h. The medium was then harvested and 
centrifuged at 1000×g for 5 min and supernatant frozen at − 80 °C prior to ELISA analysis. To examine the effect 
of hyperglycaemia cells were incubated in MCDB131 medium (Gibco) containing 10% FCS and a final con-
centration of 5 mM d-glucose (NG = normal glycaemia), 30 mM d-glucose (HG = hyperglycaemia), or 25 mM 
l-glucose + 5 mM d-glucose (OS = osmolarity control). Recombinant IGF-1 (Peprotech EC, (London, UK) and 
the PI3 kinase (PI3K) inhibitor, LY294002 (Calbiochem, Nottingham, UK) were added as indicated. MTT assays 
were performed to ensure that there was no effect of the treatments on cell viability.
Adenoviruses. The recombinant replication-deficient adenoviruses encoding constitutively active ADA 
mutant of FoxO1 (Ad-caFoxO1) was a kind gift of Professor D Acilli, Columbia University, NY, USA and domi-
nant-negative Akt (Ad-dn-Akt), myristoylated Akt (Ad-myr-Akt)60, PTEN, and PTENc/s were a kind gift of Dr 
Christopher Kontos, Duke University, USA. All adenoviruses were amplified in HEK-293 cells and isolated from 
the cells following 4 snap freeze/thaw cycles by CsCl gradient centrifugation and dialysed into 10 mM Tris HCl 
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(pH 8.0), 2 mM  MgCl2, 4% sucrose and stored at − 80 °C. Purified adenoviruses were titred using the Adeno-
X™ Rapid Titer Kit (Takara) and the optimal multiplicity of infection determined by Western blotting as we 
described  previously57,61. HUVEC were infected with 50–100 infective units (IFU)/cell and incubated for 18 h in 
MCDB131 medium containing 5% FCS prior to the experiment.
Experimental animals. All procedures involving animals were performed in accordance with protocols 
and regulations approved by the University of Birmingham Animal Welfare Ethics Review Body, under a licence 
issued in accordance with the Animals (Scientific Procedures) Act 1986, adopting the principles of the 3Rs 
(Replacement, Reduction and Refinement), and carried out in compliance with the ARRIVE guidelines for ani-
mal study (http:// www. nc3rs. org. uk/ page. asp? id= 1357).
FVB/N mice at 10-to-12 weeks of age were housed in a temperature, humidity, and light-controlled room 
with a 12-h light/dark cycle and allowed free access to water and food. The mice were divided into two age- and 
sex-matched groups (8 mice per group), housed in different cages, and injected via the tail vein with recombi-
nant adenovirus (2 ×  1010 IFU) encoding caFoxO1 or Ad-CMV empty control virus. After 48 h the mice were 
euthanized and blood was collected by cardiac puncture to obtain plasma, and the livers snap-frozen for the 
preparation of mRNA, by an individual blinded to the original treatment.
siRNA‑mediated gene knock‑down. siRNAs targeted to human FOXO1, FOXO3A, AKT1 and VEGF 
were introduced into HUVEC using the Amaxa Nucleofector HUVEC II kit according (Amaxa) as we described 
 previously61, or Lipofectamine RNAiMax transfection reagent (Thermo Fisher) following the manufacturer’s 
recommended protocol. Following transfection the cells were incubated for 18  h overnight prior to further 
treatment. The siRNA sequences were selected based on previously reported efficacy as follows: FOXO1, 5′-AAG 
AGC GUG CCC UAC UUC AAG-3′42,49; FOXO3A, 5′-AAG AGC UCU UGG U GGA UCA UC-3′42,49; VEGF, 5’-AAG 
GAG UAC CCU GAU GAG AUC-3′62; Akt1, 5′-AAG GAG GGU UGG CUG CAC AAA-3′63; A universal control 
siRNA from Dharmacon was used as a negative control.
ELISA. Human and mouse PlGF levels were measured in cell supernatants using DuoSet IC ELISA kits 
according to the manufacturer’s instructions (R&D Systems). Results were expressed either as the mean con-
centration of PlGF in pg/ml of conditioned medium, or the “mean % release” calculated as a percentage of each 
sample relative to the untreated control for each experiment.
RNA isolation and real‑time qPCR. The Total RNA plus kit (Norgen Biotek Corp, Canada) was used 
to isolate RNA from cell and tissues according to the manufacturer’s instructions. Following stimulation, the 
medium was aspirated and cell monolayers were washed twice with ice-cold PBS and lysed directly in buffer RL. 
Mouse tissues were disaggregated in ice-cold buffer RL using a Precellys 24 tissue homogenizer set at 2 cycles 
a 6500 rpm for 20 s with a 30 s interval at 4 °C. Total RNA was extracted and subjected to DNase-1 digestion 
and ~ 1 μg was reverse transcribed with oligo-dT18 primers using the First Strand Synthesis Kit (Promega) for 1 h 
at 48 °C. Real-time qPCR was performed using a Rotagene RG-3000 (Qiagen) under the following amplification 
conditions: 95 °C for 10 min, followed by 45 cycles of 95 °C, 10 s; 58 °C, 10 s; 72 °C, 20 s. cDNA samples were 
amplified in triplicate using SensiMix SYBR green (Bioline) and primers specific for human and mouse PlGF, 
FOXO1, FOXO3A, VEGF and β-actin (Table S1). PCR products were analysed by 2% agarose gel electrophore-
sis, sequenced, and post-run melt curve analysis performed to ensure specificity of reactions. The mean thresh-
old cycle (Ct) for each sample was normalised to β-actin levels and fold changes to the experimental control 
calculated using the ΔΔCt method.
Western blotting. Cell monolayers were washed twice with ice-cold PBS and lysed directly in ice-cold 
RIPA buffer (Pierce) containing a phosphatase and complete protease inhibitors (Roche) and a total of 30 μg 
protein of each sample run on 10% SDS-PAGE gels, and blotted onto nitrocellulose or PVDF membranes as 
 described57. Membranes were blocked in TBS-T (25 mM Tris–HCl, pH 7.5, 150 mM NaCl, and 0.1% Tween 20) 
containing 5% (w/v) fat-free milk for 1–2 h and incubated with primary antibodies at the concentration indi-
cated (Table S2) in TBS-T containing 5% BSA overnight at 4 °C. After washing in TBS-T (4 × 10 min), the blots 
were incubated for 1 h with a 1:10,000 dilution of the appropriate horseradish peroxidase-conjugated antibody 
(Cell Signalling Technologies) in TBS-T containing 5% (w/v) fat-free milk for 1 h at room temperature and 
proteins detected by enhanced chemiluminescence. Following the detection of phosphorylated Akt, or FOXO1 
membranes were stripped in NaOH (200 mM) for 20 min at room temperature and re-probed for total Akt or 
FOXO1 protein respectively and β-actin, or α/β tubulin used as a loading control.
ChIP assays. Endothelial cells were grown to ~ 80% confluence 15 cm culture dishes and treated under the 
conditions indicated under Cell Culture above. The cells (~ 1 ×  107/sample) were fixed/chromatin cross-linked 
for 10 min using methanol-free formaldehyde (Pierce) added directly to the culture medium to a final con-
centration of 1%64. The formaldehyde was then quenched by adding 2 M glycine to a final concentration of 
125 mM and cells washed twice with ice-cold  PBS64,65. The cells were then scrapped into ice-cold PBS, pelleted 
and lysed in 50 mM HEPES (pH 8.0) containing, 150 mM NaCl, 10 mM EDTA, 10% glycerol, 0.25% Triton 
X-100 and complete protease inhibitor cocktail (Roche) and incubated for 10 min at 4 °C with end-over-end 
 rotation64,65. Nuclei were collected by centrifugation and resuspended in ice-cold wash buffer (10 mM HEPES, 
10 mM EDTA, 0.5 mM EGTA, 0.25% Triton X-100, (pH 8), complete protease inhibitors on a rotary mixer. The 
nuclei were sonicated on ice using Bioruptor (Diagenode, USA) set on “high” (240 W) with 20–25 cycles of 30 
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secs ON; 30 secs OFF to give fragmented DNA of ~ 100–300 bp. The sonicated material was then centrifuged for 
10 min at 16,000×g at 4 °C and the supernatants harvested. Chromatin was diluted with ChIP buffer (25 mM 
Tris–HCl (pH 8.0), 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.25% SDS, 0.1 mM PMSF and complete 
protease  inhibitors65) and 50 μL was kept as the “input” and the rest immunoprecipitated using 10 µg of rabbit 
anti-FOXO1 (H-128, Santa Cruz Biotechnology, USA), rabbit anti-RNA Pol II (ab26721, Abcam, UK), or iso-
type-matched IgG as positive and negative controls respectively. The antibody was added with BSA (0.5% final 
concentration) to 10 µl of protein A/G magnetic beads (Pierce), following washing and resuspension in 100 mM 
phosphate buffer, and incubated for 2 h at 4 °C on a rotary mixer. The chromatin cross-links were reversed by 
adding 1 μl of RNAse A (10 mg/ml) with 30 min incubation. Chromatin was subjected to qPCR in triplicate with 
primers flanking the putative FOXO1 DNA binding sequence identified in the PlGF promoter (5’-AGA GCA 
CCA AGC ACA CCT GTTT-3 and 5’-CAG TGC CCA CAA CTC AAC AC-3’) and proximal to the PlGF transcrip-
tional start site (5’-CCA TTC GAC ATA TGC AGG CA-3’ and 5’-CAT GAT CTA ACC GCC TCT GC-3’). A negative 
control region (NegC; ActiveMotif, UK) was used to calculate the relative enrichment. Input chromatin was used 
to generate an amplification curve for each primer set to determine the amount of DNA immunoprecipitated 
with anti-FOXO1, Pol II and isotype-matched IgG control antibodies. Binding data are presented as the mean 
fold-enrichment at the putative FOXO1 concensus site, or adjacent to the PlGF transcriptional start site, relative 
to the negative control region (NegC; ActiveMotif) based on the percentage of input obtained.
Statistical analysis. All data are expressed as the mean ± SD or SEM as indicated. Statistical analysis was 
performed with GraphPad PRISM using either an unpaired, two-tailed Student’s t-test, or non-parametric one-
way ANOVA with Tukey’s multiple comparison post hoc test. A P value of < 0.05 was considered statistically 
significant (*P < 0.05; **P < 0.01).
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